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Objective. To validate the European League
■
Against Rheumatism (EULAR), the American College 
of Rheumatology (ACR), and the World Health Or-
*
ganization (WHO)/International League Against Rheu­
matism (ILAR) response criteria for rheumatoid arthri­
tis (R A).
h
Methods. EULAR response criteria were devel­
oped combining change from baseline and level of 
disease activity attained during foliowup. In a trial 
comparing hydroxychloroquine and sulfasalazine, we
»
studied construct (radiographic progression), criterion 
(functional capacity), and discriminant validity.
Results. EULAR response criteria had good con- 
struct, criterion, and discriminant validity. ACR and 
WHO/ILAR criteria showed only good criterion validity.
Conclusion. EULAR response criteria showed 
better construct and discriminant validity than did the 
ACR and the WHO/ILAR response criteria for RA.
and functional impairment. Because the pathogenesis
■
of RA is still unknown, antirheumatic therapies are 
focused on nonspecific suppression of disease activity. 
Patients with RA have various manifestations of the
V
disease, and therefore, disease activity cannot be 
expressed by a single parameter of inflammation. An 
index of disease activity should combine measure­
ments representing several aspects of the disease (1). 
The Disease Activity Score (DAS) is such a validated 
index. It combines the Ritchie articular index (2), a 
count of swollen joints, the erythrocyte sedimentation 
rate (ESR), and an assessment of the patient’s general 
health (3).
In general, the efficacy of a treatment is deter­
mined by comparing group means of changes in dis­
ease activity variables. However, a significant differ­
ence between groups does not indicate the actual 
number of patients who responded to treatment.
Rheumatoid arthritis (RA) is a chronic systemic 
disease, with polyarthritis as its main feature. Chronic 
inflammation of the joints often leads to joint damage
Therefore, in addition to disease activity, the response 
of individual patients to antirheumatic therapy is an 
important measurement in clinical trials. Response 
criteria should include the relevant change in disease
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activity since the start of treatment, and the level of 
disease activity attained during followup (4).
Recently, 2 sets of response criteria were pro-
b
posed: the American College of Rheumatology (ACR) 
preliminary criteria for improvement (5), and the World 
Health Organization (WHO)/International League 
Against Rheumatism (ILAR) criteria for decreased 
inflammatory synovitis (6). The components of these 
criteria were selected using a judgmental approach 
rather than a statistical approach (7). On behalf of the 
EULAR Standing Committee for International Clini-
Table 1. Response criteria defined by the WHO/ILAR and the ACR*
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WHO/ILAR response criteria ACR response criteria
1. >20% improvement in swollen joint count
2. >20% improvement in tender joint count, or £5  if the count 
is between 16 and 20
3. >20% improvement in at least 2 of the following 3 measures:
A. Patient’s or physician’s assessment of global disease activity
B. Pain
C. ESR
1. 2:20% improvement in swollen joint count
2. a20%  improvement in tender joint count
3. 2:20% improvement in at least 3 of the following 5 measures:
A. Patient’s global assessment of disease activity
B. Physician’s global assessment of disease activity
C. Patient’s assessment of pain
D. Acute-phase reactant
E. Disability
* WHO = World Health Organization; ILAR = International League Against Rheumatism; ACR =  American College of Rheumatology; ESR 
= erythrocyte sedimentation rate.
cal Studies including Therapeutic Trials, it was de­
cided to develop response criteria based on a combi­
nation of the judgmental and statistical approaches. 
The validity of the newly developed EULAR criteria 
and the ACR and WHO/ILAR response criteria was 
also studied. Our findings are presented herein.
PATIENTS AND METHODS
Development of response criteria. Patients and mea­
surements. Response criteria were developed using a cohort 
of patients with recent-on set ( < 1  year) definite or classic RA
(8 ) who were attending the outpatient clinic at the University 
Hospital Nijmegen. Between 1985 and 1994, 227 patients 
were included in the study.
Slow-acting antirheumatic drugs (SAARDs) were 
prescribed when treatment with nonsteroidal antiinflamma­
tory drugs (NSAIDs) alone was not sufficiently effective. 
Sulfasalazine (SSZ), hydroxychloroquine (HCQ), or aurano- 
fin (AUR) were regarded as first-option SAARDs. In case of 
treatment failure, aurothioglucose or methotrexate could be 
prescribed. A third option was treatment with D-penicilla- 
mine or azathioprine. Oral prednisone (10 mg) and intra- 
articular injections of steroid were allowed as adjuvant ther­
apy. Rheumatologists decided about all changes in therapy.
Patients were seen every 3 months by specially 
trained research nurses. The nurses collected clinical and 
laboratory data, including the Ritchie articular index (RAI), 
number of swollen joints, erythrocyte sedimentation rate 
(ESR, in mm/hour), and general health status (by 1 0 0 -mm 
visual analog scale). On the basis of these measurements, we 
calculated the Disease Activity Score (DAS) (3):
DAS = 0 .5 4 ( \/R A i)  + 0.065(SwJts) + 0.33(ln ESR) + 0.0072(GH)
where SwJts = the number of swollen joints and GH = 
general health status.
The measurement error of the DAS was estimated, 
using interperiod correlation matrix analysis, in patients with 
5:3 years of foliowup (n = 78). With this method, the 
assumption was made that the correlation between 2  DAS 
measurements declines as the interval in between increases. 
The intercept of the regression line (y axis: interperiod 
Pearson correlations between DAS measurements; x axis: 
intermediate time interval) was used for estimating the
measurement-remeasurement correlation r0 (correlation be­
tween DAS measurements with intermediate time interval =  
0) (9). From this r0, the measurement error (e) can be 
calculated:
e2/SD (l/r0) -  I
where SD = the standard deviation of the DAS.
Definition of response. Response was defined as 
both: (a) change in disease activity from baseline and (b) the 
level of disease activity attained during folio wup. The fol­
lowing criteria for change and attained disease activity were 
used, (a) For good response, a statistically significant de­
crease in disease activity from baseline (i.e., more than 2  
times the measurement error [2 e] [95% confidence interval =  
DAS ± 2e]), was necessary, (b) For good response, the DAS 
level attained must correspond to low levels of disease
♦  *activity.
Periods of low disease activity were defined as either 
the time during which the rheumatologist recommended that 
SAARD treatment be stopped because of remission, or 
periods of at least 1 year during which SAARD treatment 
was not started or the existing SAARD treatment was not 
changed. A high level of disease activity was defined as the 
time at which the rheumatologist decided that the patient 
should start SAARD treatment, or that the SAARD being 
taken should be changed (after a washout period of > 1  
month for SSZ or methotrexate, and > 2  months for the 
remaining SAARDs). Medical records were checked to 
correct for reasons other than high or low levels of disease 
activity that could bias the rheumatologist’s decision regard­
ing treatment (noncompliance, refusal of therapy, etc.). In 
the analyses, :s2  periods of high disease activity and 
periods of low disease activity per patient, with a time period 
between high and low activity of > 1  year, were randomly 
chosen.
Validation of response criteria. Patients and measure­
ments. In a 48-week double-blind trial comparing SSZ and 
HCQ in 60 patients with recent-onset RA (10), the EULAR 
response criteria and 2  other newly developed response 
criteria, the WHO/ILAR and the ACR criteria (Table 1), 
were validated. Twenty-five patients in the SSZ-HCQ trial 
were also included in the open (development) study. How­
ever, the overlap existed only during the first year of the 
open study ( < 1 0 % of the data); thereafter, no overlap was 
present.
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Figure 1. Distribution of Disease Activity Scores at moments of 
low (n = 89) or high (n = 189) disease activity, according to 
treatment decisions made by rheumatologists in the cohort study of 
patients with rheumatoid arthritis. The vertical lines divide the DAS 
into low (^2.4), moderate (>2.4 and ¿3.7), and high (>3.7) levels of 
disease activity (activ.).
Statistical analysis. Missing disease activity data were 
supplied by interpolation when measurements were avail­
able within 2  weeks from the missing moment. Tests were 
performed using patient moments of response: response at 
weeks 12, 24, 36, and 48 for each of the 60 patients. To 
equalize the number of patient moments available for the 
analyses of each set of response criteria, we used 186
moments of the original 240 (4 x 60), excluding moments 
with missing EULAR, modified ACR, or WHO/ILAR re­
sponses. Radiographic progression was transformed (square 
root) to “ normality.” The association between response 
(week 12, 24, 36, 48) and radiographic progression (week 48) 
was tested with analysis of variance. The association be­
tween response (week 12, 24, 36, 48) and relative change in 
HAQ score (week 12,24, 36,48) was analyzed with Kruskal- 
Wallis tests. Differences in response in both treatment 
groups were tested with Wilcoxon rank sum tests (EULAR 
response criteria: good response = 1 , moderate response = 
2, no response = 3; WHO/ILAR and modified ACR response
criteria: good response = 1 , insufficient response 0 ).
RESULTS
Disease activity variables were measured every 12 
weeks. Radiographs of the hands and feet were taken at 
baseline and at 48 weeks. Films were scored using a modi­
fication of the method of Sharp et al (1 1 ). At weeks 0 , 1 2 , 24, 
36, and 48, a Dutch equivalent of the Stanford Health 
Assessment Questionnaire (HAQ) was used to measure 
functional capacity in the last 41 consecutive patients of the 
trial ( 1 2 ).
Response was retrospectively assessed every 12 
weeks. Because the physician’s global assessment of disease 
activity was not included in the original trial, we modified the 
ACR criteria, such that patients had to fulfill 3 of the 4 
remaining measures as well as have improvement in the 
tender and swollen joint counts to be considered a re­
sponder.
Validation procedures (7). Criterion validity tests the 
accuracy of the criteria. Because no gold standard for 
response was available, we compared the criteria with each 
other and with the true clinical status, as determined by the 
functional capacity (from the HAQ). To correct for baseline 
values, the relative change in the HAQ score was evaluated 
at weeks 12, 24, 36, and 48.
Construct validity is an aspect of validity that inves­
tigates the association o f the criteria with the expected 
results (the outcome). Radiographic progression represents 
an observable biologic end point resulting from inflammation 
and enzymatic degradation of cartilage and subchondral 
bone (13). Therefore the association between response (ev­
ery 1 2  weeks) and radiographic progression (total number of 
new erosions and joint space narrowing at week 48 com­
pared to baseline) was analyzed.
Discriminant validity refers to the ability of the 
criteria to detect clinically important differences. Therefore, 
the proportion of responders in both treatment categories 
(HCQ and SSZ) was compared every 1 2  weeks.
Development of the EULAR criteria. The esti­
mated Pearson’s correlation coefficient for remeasure­
ments was 0.80, and the standard deviation of the DAS 
was 1.17, leading to a measurement error of 0.6. For 
good response, a change from baseline that exceeded 
1.2 (or 2 x 0.6) DAS points was necessary.
Disease Activity Scores during moments of 
high and low disease activity, according to the rheu­
matologists, were calculated. In 142 patients, 189 
moments of high disease activity were defined. The 
DAS ranged from 1.38 to 7.15, with a mean of 4.32. 
Eighty-nine moments of low disease activity in 56 
patients were defined. The DAS ranged from 0.59 to 
4.01, with a mean of 1.77.
To minimize the overlap between high and low 
disease activity 0^5%), 2 limits were chosen: one at 
the 75th percentile of low disease activity (DAS = 
2.4), and the other at the 25th percentile of high 
disease activity (DAS = 3.7) (Figure 1). With these
Table 2. Means (ranges) of the components of the DAS for low, 
moderate, and high levels of disease activity*
Ritchie
index
No. of 
swollen 
joints
ESR
(mm/hour)
General
health
DAS S2.4 1 (0-5) 4(0-18) 13 (1-54) 16 (0-53)
2.4 <  DAS £  3.7 5 (0-15) 10 (0-25) 29 (3-99) 33 (0-76)
DAS >3.7 14 (1-37) 18 (7-35) 45 (3-130) 51 (1-99)
* General health was quantified on a 100-mm visual analog scale, 
DAS = Disease Activity Score; ESR = erythrocyte sedimentation 
rate.
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Figure 2. European League Against Rheumatism (EULAR) re­
sponse criteria based on the Disease Activity Score (DAS) in 
patients with rheumatoid arthritis. Improvement in the DAS was 
compared with baseline; categories to the left represent the level of 
disease activity attained during followup.
limits, the DAS was divided into 3 categories: ^2.4  
(low disease activity), >2.4 and <3.7 (moderate dis­
ease activity), and >3.7 (high disease activity). The 
means and ranges of the components of the DAS are 
indicated in Table 2. Good response was defined as 
>1.2 improvement in the DAS from baseline, and a 
DAS attained during followup of ^ 2.4. Nonresponders 
were patients with an improvement of ^0.6 (le) or 
patients with an improvement of >0.6 but <1.2, and a 
DAS attained during followup of >3.7. The remaining 
patients would be classified as moderate responders 
(Figure 2).
Validation of the criteria. Response criteria 
were validated in a trial comparing SSZ and HCQ. No 
significant differences in patient characteristics were 
present at baseline (Table 3).
Criterion validity. Figure 3 shows responders 
and nonresponders according to the modified ACR 
criteria, plotted within the 3 classes of EULAR re­
sponse. The WHO/ILAR criteria showed similar re­
sults, with only 3 patients classified differently than
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Figure 3. Distribution of the modified American College of Rheu­
matology (ACR) responses over the 3 European League Against 
Rheumatism (EULAR) response categories (56 patients, 186 mo­
ments). Triangles indicate good response according to the modified 
ACR criteria, squares indicate no response according to the modi­
fied ACR criteria. Responders according to the EULAR criteria are 
shown in the upper (no response [Non]), middle (moderate response 
[Mod.]), and lower (good response [Good]) areas of the figure. The 
results with the World Health Organization/International League 
Against Rheumatism (WHO/ILAR) criteria were comparable with 
those of the ACR criteria.
with the modified ACR criteria. Responders as defined 
by the modified ACR (and WHO/ILAR) criteria were 
classified with the EULAR response criteria as good 
58% (56%), moderate 40% (42%), and no response 2% 
(2%). Nonresponders as defined by the modified ACR 
(and WHO/ILAR) response criteria were classified 
with the EULAR response criteria as good 1% (1%), 
moderate 26% (25%), and no response 72% (74%).
Table 3. Patient characteristics at baseline (treatment trial)*
Hydroxychloroquine
(n = 30)
Sulfasalazine 
(n = 30)
Sex, % female 57 68
Age, mean (range) years 53.1 (22-72) 53.5 (22-75)
Disease duration, median (range) months 8.0 (3-120) 8.5 (3-165)
IgM-RF, %  >10 IU 96 91
DAS, mean (range) 4.32 (3.07-5.87) 4.37 (2.48-6.77)
RAI, median (range) 14.0 (3-34) 11.5(1 -34)
No. of swollen joints, mean (range) 14.7 (5-26) 14.4 (5-32)
ESR, median (range) mm/hour 39.5 (5-110) 35.5 (35-120)
General health, mean (range) 28.7 (0-85) 39.0 (0-100)
No. of erosions, median (range) 1 (0-18) 0(0-17)
No. with narrowing, median (range) 2 (0-20) 0(0-10)
* There were no significant differences in characteristics between the 2 groups. IgM-RF IgM
rheumatoid factor; DAS = Disease Activity Score; RAI = Ritchie articular index; ESR = erythrocyte 
sedimentation rate.
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At weeks 12, 24, 36, and 48, treatment response 
was compared with the relative change in functional 
capacity (the HAQ) (n = 102). All 3 response criteria 
showed a good correlation with functional capacity
(P 0.0001). Patients with good response had signif-
icantly more improvement in functional capacity than 
did those with moderate response and those with no 
response (Figure 4).
Discriminant validity. The discriminating ca­
pacity of the response criteria was studied comparing 
the numbers of responders who were taking SSZ and 
HCQ (n = 186). With the EULAR response criteria, 
patients in the SSZ-treated group showed a signifi­
cantly better response (23% good, 36% moderate, and 
41% no response; n = 86) compared with the HCQ- 
treated group (12% good, 25% moderate, 63% no 
response; n = 100) (P = 0.002). With the modified 
ACR criteria (SSZ 34% good, HCQ 23% good) and the 
WHO/ILAR criteria (SSZ 35% good, HCQ 25% good), 
no significant differences could be demonstrated (P 
0.11 and P = 0.14, respectively).
Construct validity. Response according to the 
EULAR criteria was significantly associated with ra­
diographic progression of disease. Patients showing no 
response had significantly more progression in joint
destruction (n 169; P 0.0001). With the modified
ACR response criteria, a significant association was 
also found (P = 0.03). The association with the WHO/
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Figure 4. Relative change in scores on the Health Assessment 
Questionnnaire (HAQ) for categories of responders, as defined by 
the EULAR, modified ACR (mACR), and WHO/ILAR response 
criteria (n = 102), Boxes show the interquartile range; horizontal 
lines show the median; vertical lines show the range. See Figure 3 
for other definitions.
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Figure 5. Radiographic progression of disease over 48 weeks, for 
categories of responders as defined by the EULAR, modified ACR 
(mACR), and WHO/ILAR response criteria (n =  169). Boxes show 
the interquartile range; horizontal lines show the median; vertical 
lines show the range. See Figure 3 for other definitions.
ILAR response criteria was not significant (P 
(Figure 5).
0.07)
DISCUSSION
Although it has been stated that individual 
treatment response is an important outcome-of- 
interest in clinical trials, it is seldom assessed (1). Only 
mean changes in disease activity variables within and 
between groups are tested. This is partly due to the 
absence of validated, commonly accepted response 
criteria. In the past, several groups have made at­
tempts to develop response measures. These mea­
sures, comprising a set of often arbitrarily selected 
variables (14~16) and arbitrarily defined class limits 
(15,16), have sometimes not been validated (16). The 
selection of components of the ACR and WHO/ILAR 
response criteria is based on consensus, although 
there is great disagreement between the purported and 
actual judgment of disease activity by rheumatologists
(17). These and other response definitions are based 
solely on changes from baseline (5,6,14). Whether this 
change is significant or relevant (resulting in low 
disease activity) is not included in the definition. Also, 
they assume a certain percentage of improvement 
(20%) to be an equally relevant change in all variables
(18). The ACR response criteria are based on the 
capacity of the criteria to discriminate between active 
treatment and placebo. An aspect which might have an 
impact on these criteria is the bias which may occur by
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including patients being treated with ’’stable” doses of
corticosteroids (19).
The Disease Activity Score is a composite 
index of disease activity based on rheumatologists’ 
opinions of disease activity. Rheumatologists were 
unaware of the ESR, and therefore of the DAS, when 
treatment decisions were made. The DAS showed 
good correlational, criterion, and construct validity 
(3). Components of the DAS (articular index, ESR), as 
well as the DAS itself (20), were found to be sensitive 
to change (21,22).
The EULAR response criteria as presented 
here are based on change from baseline (or, measure­
ment error, which is a statistical approach) and level of 
DAS reached during foliowup (low, moderate, or high, 
based on treatment decisions, which is a judgmental 
approach) (4). They show good construct, criterion, 
and discriminant validity: they are associated with 
progression of joint damage and relative change in 
functional capacity, and they discriminate between 
therapies. The median change in the HAQ score for 
both moderate and good responders was of the same 
magnitude as has been declared to be a clinically 
important difference by Redelmeier and Lorig (23). 
The WHO/ILAR criteria show a marked association 
with functional capacity, but no association with ra­
diographic progression, and they are not sensitive to 
discriminating between SSZ and HCQ treatments. 
Apart from the component of functional capacity, the 
ACR response criteria are almost identical to the 
WHO/ILAR criteria. Because the physician’s global 
assessment was not measured in the original trial, only 
a global impression of the performance of the ACR 
criteria could be given in the present study, however. 
The association with radiographic progression was 
less strong than that found with the EULAR criteria. 
The association with functional capacity is not surpris­
ing, since disability is part of this response definition. 
The modified ACR criteria were not able to discrimi­
nate between therapies.
We compared patient responses according to 
the EULAR criteria with the responses defined by the 
WHO/ILAR and the modified ACR criteria. With the 
latter 2 sets of criteria, about 25% of the nonre­
sponders and about 40% of the responders were clas­
sified as having a moderate response by the EULAR 
criteria. We studied whether the difference in results 
(construct/discriminant validity) between the 3 criteria 
could be explained by the number of categories. 
Therefore, the performance of 2-group EULAR re­
sponse criteria (good/moderate versus no response)
was studied. The results were equal to those with our 
original 3-group response criteria, and were better 
than those with the modified ACR and the WHO/ILAR 
criteria. Redefining the modified ACR criteria into 3 
groups (good = >50%, moderate = >20%, no re­
sponse = ^20% improvement from baseline) showed 
similar associations as found with the original 2 cate­
gories. EULAR response criteria based solely on 
change from baseline (good >1.2, moderate >0.6, no 
response ^0.6) showed results that were comparable 
with those of the modified ACR and the WHO/ILAR 
criteria and were worse than those of the EULAR 
response criteria that included level of disease activity 
attained during followup (data not shown).
Tugwell and Bombardier describe 2 additional 
types of validity apart from criterion, discriminant, 
and construct validity, namely content validity and 
face validity (7). Content validity, or comprehensive­
ness of response criteria, means that all important 
components of disease activity are included in the 
criteria. The Disease Activity Score was based on 
treatment decisions made bvy rheumatologists. The 
disease activity variables best explaining these deci­
sions were selected using a statistical approach (3). 
The inclusion of other disease activity variables in the 
DAS had no additional discriminating capacity be 
tween high and low disease activity (24). The ACR and 
WHO/ILAR components were selected using a judg­
mental approach. A disadvantage of such a method is 
that some components may be duplicative; for exam­
ple, there is a high correlation between the results of 
patient’s assessment of global disease activity and 
patient’s assessment of pain, and no additional infor­
mation is gained by measuring both. The face validity 
of the response criteria, the credibility, depends on the 
willingness to accept the method and on the extent to 
which the results are interpretable. The assessment of 
response with all 3 criteria is complicated. The inter­
pretation of the results is less difficult because there 
are only 2 or 3 categories of response.
In agreement with WHO/ILAR
criteria (10), the EULAR response criteria assume a
level of baseline disease activity, that is,minimum r 
patients must have the potential to improve signifi­
cantly (>1.2) to become good responders. A DAS <  
1.0 indicates the absence of disease activity; therefore, 
the baseline value of the DAS has to be >2.2 (1.0 + 
1.2) to define response. This could also serve as an 
inclusion term for clinical trials.
The DAS is a continuous variable 
developed to describe the disease process. EULAR
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response criteria give an interpretation of the (change 
in) DAS for individual patients. We conclude that 
EULAR response criteria have construct validity, 
criterion validity, and discriminant validity. However, 
the performance of these criteria in comparison with 
others has to be studied further in future clinical trials 
comparing different treatment regimens in different 
patient populations. Also the performance of response 
criteria based on the modified DAS (including 28-joint 
counts) will be evaluated.
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